High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells

Hsiang Chun Lin, Chao-Liang Wu, Yuh-Ling Chen, Jehn-Shun Huang, Dung-Yau Wang, Kuo Yuan

研究成果: Article

8 引文 (Scopus)

摘要

Objectives: The β1 integrin (CD29) is a putative marker for cancerous epithelial stem cells. Cancer stem cells are essential to drive tumor growth, recurrence, and metastasis. We investigated the role of β1-integrin expression in the development of malignant phenotypes of oral squamous cell carcinoma (OSCC). Materials and methods: Immunostaining was used to analyze the expression levels of β1 integrins in different types of cell colonies and tumor spheres. The results of cell viability and migration assays with and without siRNA knockdown of β1-integrin expression were compared. Cells expressing β1 integrins were evaluated for their tumorigenicity in mice. The expression of β1 integrins in human specimens of oral cancers at different clinical stages was semiquantified based on immunohistochemical staining of the β1-integrin protein. Results: The expression level of β1 integrins in Meng-1 oral epidermoid carcinoma cells (OECM-1) cells was significantly higher in holoclonal colonies and tumor spheres compared to control cells. The knockdown of β1-integrin expression in OECM-1 cells reduced cell proliferation, migration, and tumor sphere formation. Beta-1 integrin (+) cells were more tumorigenic in the mouse xenograft model than β1 integrin (-) cells. In the human specimens, the expression level of the β1-integrin protein positively correlated with the clinical stage. Conclusion: The expression of β1 integrin in OECM-1 cells is involved in the development of malignant phenotypes of OSCC. Clinical relevance: Inhibitors for β1-integrin signaling may be suitable to become target-specific therapies for OSCC.

原文English
頁(從 - 到)1277-1284
頁數8
期刊Clinical Oral Investigations
18
發行號4
DOIs
出版狀態Published - 2014 一月 1

指紋

Mouth Neoplasms
Integrins
Squamous Cell Carcinoma
Neoplasms
Cell Migration Assays
Integrin beta Chains
Phenotype
Neoplastic Stem Cells
Heterografts
Small Interfering RNA
Cell Movement
Cell Survival
Proteins
Stem Cells
Epithelial Cells

All Science Journal Classification (ASJC) codes

  • Dentistry(all)

引用此文

@article{1ce6b5d62d114b1f96d6d37c170f734d,
title = "High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells",
abstract = "Objectives: The β1 integrin (CD29) is a putative marker for cancerous epithelial stem cells. Cancer stem cells are essential to drive tumor growth, recurrence, and metastasis. We investigated the role of β1-integrin expression in the development of malignant phenotypes of oral squamous cell carcinoma (OSCC). Materials and methods: Immunostaining was used to analyze the expression levels of β1 integrins in different types of cell colonies and tumor spheres. The results of cell viability and migration assays with and without siRNA knockdown of β1-integrin expression were compared. Cells expressing β1 integrins were evaluated for their tumorigenicity in mice. The expression of β1 integrins in human specimens of oral cancers at different clinical stages was semiquantified based on immunohistochemical staining of the β1-integrin protein. Results: The expression level of β1 integrins in Meng-1 oral epidermoid carcinoma cells (OECM-1) cells was significantly higher in holoclonal colonies and tumor spheres compared to control cells. The knockdown of β1-integrin expression in OECM-1 cells reduced cell proliferation, migration, and tumor sphere formation. Beta-1 integrin (+) cells were more tumorigenic in the mouse xenograft model than β1 integrin (-) cells. In the human specimens, the expression level of the β1-integrin protein positively correlated with the clinical stage. Conclusion: The expression of β1 integrin in OECM-1 cells is involved in the development of malignant phenotypes of OSCC. Clinical relevance: Inhibitors for β1-integrin signaling may be suitable to become target-specific therapies for OSCC.",
author = "Lin, {Hsiang Chun} and Chao-Liang Wu and Yuh-Ling Chen and Jehn-Shun Huang and Dung-Yau Wang and Kuo Yuan",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00784-013-1088-y",
language = "English",
volume = "18",
pages = "1277--1284",
journal = "Clinical Oral Investigations",
issn = "1432-6981",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - High-level β1-integrin expression in a subpopulation of highly tumorigenic oral cancer cells

AU - Lin, Hsiang Chun

AU - Wu, Chao-Liang

AU - Chen, Yuh-Ling

AU - Huang, Jehn-Shun

AU - Wang, Dung-Yau

AU - Yuan, Kuo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives: The β1 integrin (CD29) is a putative marker for cancerous epithelial stem cells. Cancer stem cells are essential to drive tumor growth, recurrence, and metastasis. We investigated the role of β1-integrin expression in the development of malignant phenotypes of oral squamous cell carcinoma (OSCC). Materials and methods: Immunostaining was used to analyze the expression levels of β1 integrins in different types of cell colonies and tumor spheres. The results of cell viability and migration assays with and without siRNA knockdown of β1-integrin expression were compared. Cells expressing β1 integrins were evaluated for their tumorigenicity in mice. The expression of β1 integrins in human specimens of oral cancers at different clinical stages was semiquantified based on immunohistochemical staining of the β1-integrin protein. Results: The expression level of β1 integrins in Meng-1 oral epidermoid carcinoma cells (OECM-1) cells was significantly higher in holoclonal colonies and tumor spheres compared to control cells. The knockdown of β1-integrin expression in OECM-1 cells reduced cell proliferation, migration, and tumor sphere formation. Beta-1 integrin (+) cells were more tumorigenic in the mouse xenograft model than β1 integrin (-) cells. In the human specimens, the expression level of the β1-integrin protein positively correlated with the clinical stage. Conclusion: The expression of β1 integrin in OECM-1 cells is involved in the development of malignant phenotypes of OSCC. Clinical relevance: Inhibitors for β1-integrin signaling may be suitable to become target-specific therapies for OSCC.

AB - Objectives: The β1 integrin (CD29) is a putative marker for cancerous epithelial stem cells. Cancer stem cells are essential to drive tumor growth, recurrence, and metastasis. We investigated the role of β1-integrin expression in the development of malignant phenotypes of oral squamous cell carcinoma (OSCC). Materials and methods: Immunostaining was used to analyze the expression levels of β1 integrins in different types of cell colonies and tumor spheres. The results of cell viability and migration assays with and without siRNA knockdown of β1-integrin expression were compared. Cells expressing β1 integrins were evaluated for their tumorigenicity in mice. The expression of β1 integrins in human specimens of oral cancers at different clinical stages was semiquantified based on immunohistochemical staining of the β1-integrin protein. Results: The expression level of β1 integrins in Meng-1 oral epidermoid carcinoma cells (OECM-1) cells was significantly higher in holoclonal colonies and tumor spheres compared to control cells. The knockdown of β1-integrin expression in OECM-1 cells reduced cell proliferation, migration, and tumor sphere formation. Beta-1 integrin (+) cells were more tumorigenic in the mouse xenograft model than β1 integrin (-) cells. In the human specimens, the expression level of the β1-integrin protein positively correlated with the clinical stage. Conclusion: The expression of β1 integrin in OECM-1 cells is involved in the development of malignant phenotypes of OSCC. Clinical relevance: Inhibitors for β1-integrin signaling may be suitable to become target-specific therapies for OSCC.

UR - http://www.scopus.com/inward/record.url?scp=84899960367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899960367&partnerID=8YFLogxK

U2 - 10.1007/s00784-013-1088-y

DO - 10.1007/s00784-013-1088-y

M3 - Article

C2 - 23982443

AN - SCOPUS:84899960367

VL - 18

SP - 1277

EP - 1284

JO - Clinical Oral Investigations

JF - Clinical Oral Investigations

SN - 1432-6981

IS - 4

ER -